All Comparisons
BPC-157 vs TB-500
Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.
BPC-157: CTB-500: D
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed. |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. It engages ERK1/2 signaling, activating c-Fos, c-Jun, and EGR-1 transcription factors... | TB-500 works primarily through actin sequestration — it binds to G-actin monomers, preventing premature polymerization, which allows repair cells to migrate rapidly to injured areas. Research in Trends in Cell Biology showed Tβ4 acts as a "battery for cell movement." It promotes angiogenesis by stim... |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | <2 hours plasma half-life; tissue effects persist 2–3 days |
| Bioavailability | IM: 15-19% (rats), 45-51% (dogs); resistant to stomach acid degradation | Subcutaneous injection; rapid systemic distribution |
| Molecular Weight | ~1419.5 g/mol | ~889 g/mol |
| WADA Status | Prohibited | Prohibited |
| Dosing | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials, Once daily (Subcutaneous (preferred), Intramuscular, or Oral) | 500–1000 mcg/day SC (~5 mg/week average), Once daily (Subcutaneous) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Removed from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility. Previously prohibited from compounding under Category 2 since September 2023. WADA-banned. | Not FDA-approved. Removed from Category 2 on April 15, 2026. PCAC review pending July 2026. Previously classified as Category 2 since September 2023. WADA-banned (S2 growth factor). |
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.